Effects of a Flaxseed-Derived Lignan Supplement in Type 2 Diabetic Patients: A Randomized, Double-Blind, Cross-Over Trial

An Pan; Jianqin Sun; Yanqiu Chen; Xingwang Ye; Huaixing Li; Zhijie Yu; Yanfang Wang; Wenjia Gu; Xinyi Zhang; Xiafei Chen; Demark-Wahnefried, Wendy; Yong Liu; Xu Lin
November 2007
PLoS Clinical Trials;Nov2007, Vol. 4 Issue 11, p1
Academic Journal
Background. Flaxseed consumption has been shown to improve blood lipids in humans and flaxseed-derived lignan has been shown to enhance glycemic control in animals. The study aimed to investigate the effect of a flaxseed-derived lignan supplement on glycemic control, lipid profiles and insulin sensitivity in type 2 diabetic patients. Methodology/Principal Findings. This was a randomized, double-blind, placebo-controlled, cross-over trial and it was conducted between April and December 2006 in Shanghai, China. Seventy-three type 2 diabetic patients with mild hypercholesterolemia were enrolled into the study. Patients were randomized to supplementation with flaxseed-derived lignan capsules (360 mg lignan per day) or placebo for 12 weeks, separated by an 8-week wash-out period. HbA1c, lipid profiles, insulin resistance index and inflammatory factors were measured. Sixty-eight completed the study and were included in the analyses. The lignan supplement significantly improved glycemic control as measured by HbA1c (-0.10±0.65 % vs. 0.09±0.52 %, P= 0.001) compared to placebo; however, no significant changes were observed in fasting glucose and insulin concentrations, insulin resistance and blood lipid profiles. Urinary excretion of lignan metabolites (enterodiol and enterolactone) was significantly higher after the lignan supplement intervention compared to baseline (14.2±18.1 vs. 1.2±2.4 µg/mL, P<0.001). Data also suggested minimal competition between lignan and isoflavones for bioavailability when measured by the excretion concentrations. Conclusions/Significance. Daily lignan supplementation resulted in modest, yet statistically significant improvements in glycemic control in type 2 diabetic patients without apparently affecting fasting glucose, lipid profiles and insulin sensitivity. Further studies are needed to validate these findings and explore the efficacy of lignans on type 2 diabetes.


Related Articles

  • Effect of Folic Acid Supplementation on Indices of Glycemic Control, Insulin Resistance and Lipid Profile in Patients With Type 2 Diabetes Mellitus. Aghamohammadi khiavi, V.; Pourghassem Gargari, B.; Aliasgharzadeh, A. // Iranian Journal of Endocrinology & Metabolism;Nov2011, Vol. 13 Issue 4, p424 

    Introduction: This study was performed to determine the effects of supplementation of folate on indices of glycemic control, insulin resistance and lipid profile in in men with type 2 diabetes, under metformin (at least 1500mg daily) treatment. Materials and Methods: This was a double-blind...

  • Light therapy for better mood and insulin sensitivity in patients with major depression and type 2 diabetes: a randomised, double-blind, parallel-arm trial. Brouwer, Annelies; van Raalte, Daniël H.; Diamant, Michaela; Rutters, Femke; van Someren, Eus J. W.; Snoek, Frank J.; Beekman, Aartjan T. F.; Bremmer, Marijke A. // BMC Psychiatry;2015, Vol. 15 Issue 1, p1 

    Background: Major depression and type 2 diabetes often co-occur. Novel treatment strategies for depression in type 2 diabetes patients are warranted, as depression in type 2 diabetes patients is associated with poor prognosis and treatment results. Major depression and concurrent sleep disorders...

  • Degludec, a New Ultra-long-acting Basal Insulin for Diabetes.  // Neurology Alert;Jul2012 Clinical Briefs in, p13 

    The article discusses a controlled trial in type 2 diabetic patients to compare degludec with glargine as part of a basal-bolus regimen, referencing a study by A. J. Garber and colleagues that was published in a 2012 issue of the "Lancet."

  • Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes. Oster, Gerry; Sullivan, Sean D.; Dalal, Mehul R.; Kazemi, Mahmood R.; Rojeski, Maria; Wysham, Carol H.; Sung, Jennifer; Johnstone, Bryan; Cali, Anna M.G.; Wei, L.J.; Traylor, Louise; Anhalt, Henry; Hull, Michelle; Van Vleet, John; Meneghini, Luigi F. // Postgraduate Medicine;Nov2016, Vol. 128 Issue 8, p731 

    Objective: This study aims to compare the effectiveness of insulin glargine 300 U/mL (Gla-300) with its accompanying patient support program with that of other basal insulin and available patient support programs in patients with type 2 diabetes (T2D) in a real-world setting in...

  • Prevention of Diabetes With Pioglitazone in ACT NOW. DeFronzo, Ralph A.; Tripathy, Devjit; Schwenke, Dawn C.; Banerji, MaryAnn; Bray, George A.; Buchanan, Thomas A.; Clement, Stephen C.; Gastaldelli, Amalia; Henry, Robert R.; Kitabchi, Abbas E.; Mudaliar, Sunder; Ratner, Robert E.; Stentz, Frankie B.; Musi, Nicolas; Reaven, Peter D. // Diabetes;Nov2013, Vol. 62 Issue 11, p3920 

    We examined the metabolic characteristics that attend the development of type 2 diabetes (T2DM) in 441 impaired glucose tolerance (IGT) subjects who participated in the ACT NOW Study and had complete end-of-study metabolic measurements. Subjects were randomized to receive pioglitazone (PGZ; 45...

  • Evaluation of Liver Function in Type 2 Diabetic Patients During Clinical Trials. Lebovitz, Harold E.; Kreider, Margaret; Freed, Martin I. // Diabetes Care;May2002, Vol. 25 Issue 5, p815 

    Presents a study that assessed whether the idiosyncratic liver toxicity reported with troglitazone is molecule-specific or a thiazolidinedione class effect. Analysis of data obtained from rosiglitazone monotherapy; Baseline demographic and clinical characteristics; Effectiveness of...

  • The Combined Effect of Triple Therapy With Rosiglitazone, Metformin, and Insulin Aspart in Type 2 Diabetic Patients. Poulsen, Mikael KÆr; Henriksen, Jan Erik; Hother-Nielsen, Ole; Beck-Nielsen, Henning // Diabetes Care;Dec2003, Vol. 26 Issue 12, p3273 

    OBJECTIVE — Type 2 diabetes is caused by reduced insulin secretion and insulin resistance in skeletal muscle and liver. We tested the combination therapy with insulin aspart, rosiglitazone, and metformin with the purpose of treating all three defects in order to test the hypothesis that...

  • Erratum to: Targeting the association of calgranulin B (S100A9) with insulin resistance and type 2 diabetes. Ortega, Francisco; Mercader, Josep; Moreno-Navarrete, José; Sabater, Mónica; Pueyo, Neus; Valdés, Sergio; Ruiz, Bartomeu; Luche, Elodie; Serino, Matteo; Naon, Deborah; Ricart, Wifredo; Botas, Patricia; Delgado, Elias; Burcelin, Remy; Frühbeck, Gema; Bosch, Fatima; Mingrone, Gertrude; Zorzano, Antonio; Fernández-Real, José // Journal of Molecular Medicine;Apr2013, Vol. 91 Issue 4, p535 

    A correction to the article "Targeting the Association of Calgranulin B (S100A9) With Insulin Resistance and Type 2 Diabetes" that was published in the March 8, 2013 issue is presented.

  • Homeostasis Model Assessment as a Clinical Index of Insulin Resistance in Type 2 Diabetic Patients Treated With Sulfonylureas. Emoto, Masanori; Nishizawa, Yoshiki; Maekawa, Kiyoshi; Hiura, Yoshikazu; Kanda, Hiroyuki; Kawagishi, Takahiko; Shoji, Tetsuo; Okuno, Yasuhisa; Morii, Hirotoshi // Diabetes Care;May99, Vol. 22 Issue 5, p818 

    Presents information on a study which investigated whether homeostasis model assessment is associated with the insulin euglycemic-hyperinsulinemic clamp in a restrospective analysis in type two diabetic patients treated with sulfonylureas. Research design and methods; Results; Conclusions.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics